Pentwater Capital Management’s Cytokinetics CYTK Stock Holding History

Pentwater Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-300,000	Closed	-$16.5M	–	86
2025 Q3	$16.5M	Hold	300,000	–	–	0.09%	66
2025 Q2	$9.91M	Buy	300,000 +80,000	+36%	+$2.78M	0.06%	65
2025 Q1	$8.84M	Sell	220,000 -870,000	-80%	-$40M	0.07%	65
2024 Q4	$51.3M	Sell	1,090,000 -10,000	-0.9%	-$519K	0.57%	29
2024 Q3	$58.1M	Sell	1,100,000 -19,000	-2%	-$1.06M	0.6%	32
2024 Q2	$60.6M	Buy	1,119,000 +39,000	+4%	+$2.35M	0.78%	29
2024 Q1	$75.7M	Buy	+1,080,000	New	+$83.5M	0.78%	21

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Pentwater Capital Management's CYTK Position: Q4 2025 in Review

Pentwater Capital Management sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 300,000 shares — an estimated $16.5M sold.

Pentwater Capital Management first reported a position in CYTK in Q1 2024 and held it in 7 quarters. The position peaked at $75.7M in Q1 2024. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

Pentwater Capital Management reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
Pentwater Capital Management sold 300,000 Cytokinetics shares in Q4 2025, an estimated $16.5M.
Pentwater Capital Management first reported a position in Cytokinetics in Q1 2024 and held it in 7 quarters.
Pentwater Capital Management's Cytokinetics position peaked at $75.7M in Q1 2024.
430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Pentwater Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.